COVID-19 Impact on Global PD-1 and PD-L1 Inhibitors Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by PD-1 and PD-L1 Inhibitors Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 PD-1 Inhibitors
  • 1.4.3 PD-L1 Inhibitors
• 1.5 Market by Application
  • 1.5.1 Global PD-1 and PD-L1 Inhibitors Market Share by Application: 2020 VS 2026
  • 1.5.2 Advanced Melanoma
  • 1.5.3 Non-small Cell Lung Cancer (NSCLC)
  • 1.5.4 Renal Cell Carcinoma
  • 1.5.5 Bladder Cancer
  • 1.5.6 Others
• 1.6 Coronavirus Disease 2019 (Covid-19): PD-1 and PD-L1 Inhibitors Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the PD-1 and PD-L1 Inhibitors Industry
    • 1.6.1.1 PD-1 and PD-L1 Inhibitors Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and PD-1 and PD-L1 Inhibitors Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for PD-1 and PD-L1 Inhibitors Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 PD-1 and PD-L1 Inhibitors Market Perspective (2015-2026)
• 2.2 PD-1 and PD-L1 Inhibitors Growth Trends by Regions
  • 2.2.1 PD-1 and PD-L1 Inhibitors Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 PD-1 and PD-L1 Inhibitors Historic Market Share by Regions (2015-2020)
  • 2.2.3 PD-1 and PD-L1 Inhibitors Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 PD-1 and PD-L1 Inhibitors Market Growth Strategy
  • 2.3.6 Primary Interviews with Key PD-1 and PD-L1 Inhibitors Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top PD-1 and PD-L1 Inhibitors Players by Market Size
  • 3.1.1 Global Top PD-1 and PD-L1 Inhibitors Players by Revenue (2015-2020)
  • 3.1.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global PD-1 and PD-L1 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global PD-1 and PD-L1 Inhibitors Market Concentration Ratio
  • 3.2.1 Global PD-1 and PD-L1 Inhibitors Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by PD-1 and PD-L1 Inhibitors Revenue in 2019
• 3.3 PD-1 and PD-L1 Inhibitors Key Players Head office and Area Served
• 3.4 Key Players PD-1 and PD-L1 Inhibitors Product Solution and Service
• 3.5 Date of Enter into PD-1 and PD-L1 Inhibitors Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global PD-1 and PD-L1 Inhibitors Historic Market Size by Type (2015-2020)
• 4.2 Global PD-1 and PD-L1 Inhibitors Forecasted Market Size by Type (2021-2026)

5 PD-1 and PD-L1 Inhibitors Breakdown Data by Application (2015-2026)

• 5.1 Global PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020)
• 5.2 Global PD-1 and PD-L1 Inhibitors Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America PD-1 and PD-L1 Inhibitors Market Size (2015-2020)
• 6.2 PD-1 and PD-L1 Inhibitors Key Players in North America (2019-2020)
• 6.3 North America PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020)
• 6.4 North America PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe PD-1 and PD-L1 Inhibitors Market Size (2015-2020)
• 7.2 PD-1 and PD-L1 Inhibitors Key Players in Europe (2019-2020)
• 7.3 Europe PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020)
• 7.4 Europe PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020)

8 China

• 8.1 China PD-1 and PD-L1 Inhibitors Market Size (2015-2020)
• 8.2 PD-1 and PD-L1 Inhibitors Key Players in China (2019-2020)
• 8.3 China PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020)
• 8.4 China PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan PD-1 and PD-L1 Inhibitors Market Size (2015-2020)
• 9.2 PD-1 and PD-L1 Inhibitors Key Players in Japan (2019-2020)
• 9.3 Japan PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020)
• 9.4 Japan PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia PD-1 and PD-L1 Inhibitors Market Size (2015-2020)
• 10.2 PD-1 and PD-L1 Inhibitors Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020)
• 10.4 Southeast Asia PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020)

11 India

• 11.1 India PD-1 and PD-L1 Inhibitors Market Size (2015-2020)
• 11.2 PD-1 and PD-L1 Inhibitors Key Players in India (2019-2020)
• 11.3 India PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020)
• 11.4 India PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America PD-1 and PD-L1 Inhibitors Market Size (2015-2020)
• 12.2 PD-1 and PD-L1 Inhibitors Key Players in Central & South America (2019-2020)
• 12.3 Central & South America PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020)
• 12.4 Central & South America PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Merck
  • 13.1.1 Merck Company Details
  • 13.1.2 Merck Business Overview and Its Total Revenue
  • 13.1.3 Merck PD-1 and PD-L1 Inhibitors Introduction
  • 13.1.4 Merck Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020))
  • 13.1.5 Merck Recent Development
• 13.2 Novartis
  • 13.2.1 Novartis Company Details
  • 13.2.2 Novartis Business Overview and Its Total Revenue
  • 13.2.3 Novartis PD-1 and PD-L1 Inhibitors Introduction
  • 13.2.4 Novartis Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)
  • 13.2.5 Novartis Recent Development
• 13.3 Roche
  • 13.3.1 Roche Company Details
  • 13.3.2 Roche Business Overview and Its Total Revenue
  • 13.3.3 Roche PD-1 and PD-L1 Inhibitors Introduction
  • 13.3.4 Roche Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)
  • 13.3.5 Roche Recent Development
• 13.4 AstraZeneca
  • 13.4.1 AstraZeneca Company Details
  • 13.4.2 AstraZeneca Business Overview and Its Total Revenue
  • 13.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Introduction
  • 13.4.4 AstraZeneca Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)
  • 13.4.5 AstraZeneca Recent Development
• 13.5 Pfizer
  • 13.5.1 Pfizer Company Details
  • 13.5.2 Pfizer Business Overview and Its Total Revenue
  • 13.5.3 Pfizer PD-1 and PD-L1 Inhibitors Introduction
  • 13.5.4 Pfizer Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)
  • 13.5.5 Pfizer Recent Development
• 13.6 GlaxoSmithKline Plc
  • 13.6.1 GlaxoSmithKline Plc Company Details
  • 13.6.2 GlaxoSmithKline Plc Business Overview and Its Total Revenue
  • 13.6.3 GlaxoSmithKline Plc PD-1 and PD-L1 Inhibitors Introduction
  • 13.6.4 GlaxoSmithKline Plc Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)
  • 13.6.5 GlaxoSmithKline Plc Recent Development
• 13.7 Jiangsu HengRui Medicine Co.,Ltd
  • 13.7.1 Jiangsu HengRui Medicine Co.,Ltd Company Details
  • 13.7.2 Jiangsu HengRui Medicine Co.,Ltd Business Overview and Its Total Revenue
  • 13.7.3 Jiangsu HengRui Medicine Co.,Ltd PD-1 and PD-L1 Inhibitors Introduction
  • 13.7.4 Jiangsu HengRui Medicine Co.,Ltd Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)
  • 13.7.5 Jiangsu HengRui Medicine Co.,Ltd Recent Development
• 13.8 Innovent + Eli Lilly
  • 13.8.1 Innovent + Eli Lilly Company Details
  • 13.8.2 Innovent + Eli Lilly Business Overview and Its Total Revenue
  • 13.8.3 Innovent + Eli Lilly PD-1 and PD-L1 Inhibitors Introduction
  • 13.8.4 Innovent + Eli Lilly Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)
  • 13.8.5 Innovent + Eli Lilly Recent Development
• 13.9 Bristol Myers Squibb (BMS)
  • 13.9.1 Bristol Myers Squibb (BMS) Company Details
  • 13.9.2 Bristol Myers Squibb (BMS) Business Overview and Its Total Revenue
  • 13.9.3 Bristol Myers Squibb (BMS) PD-1 and PD-L1 Inhibitors Introduction
  • 13.9.4 Bristol Myers Squibb (BMS) Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)
  • 13.9.5 Bristol Myers Squibb (BMS) Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer